Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for cessation of smokeless tobacco use in non-smokers
2008-000546-31Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nicotine dependence comparing Varenicline (Champix) with Placebo (2 arms). Primary endpoint: 4-week Continuous Quit Rate (CQR) at end of treatment. Started May 2008; status: completed.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2008-000546-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000546-31.